Sirolimus Tablets

Description

Drug name: Rapamune

Generic name: Sirolimus

Drug class: mTOR inhibitor

Indication: Rapamune is indicated for the prevention of organ rejection in kidney transplant patients aged 13 years and older. It may also be used in combination with other immunosuppressive agents for the prevention of rejection in liver and heart transplant patients.

Dosage form: Oral tablet

Strengths: 0.5 mg, 1 mg, 2 mg, and 5 mg tablets

Dosing instructions: The initial dose of Rapamune is typically 6 mg, followed by 2 mg daily. Dosage adjustments may be necessary based on the patient’s clinical response and trough blood concentrations.

Common side effects: Common side effects of Rapamune include mouth sores, diarrhea, headache, and acne. It may also increase the risk of developing lymphoma and other malignancies.

Contraindications: Rapamune is contraindicated in patients with a known hypersensitivity to sirolimus or any of its components. It should also not be used in patients with liver dysfunction or a history of angioedema.

Precautions: Patients taking Rapamune should be monitored for signs of infection and malignancy. It may also interact with other medications, including strong inhibitors or inducers of CYP3A4, and medications that affect the immune system.

Pregnancy and breastfeeding: Rapamune is classified as pregnancy category C and should be used during pregnancy only if the potential benefits justify the potential risks to the fetus. It is not known whether sirolimus is excreted in human milk, so caution should be exercised when administering Rapamune to nursing women.